Appointments at Catalent, Quintiles, ACM and Premier Research – People on the move

Catalent Pharma Solutions​ has made a number of appointments. Scott Neilson​, formerly of AAI Pharma and Covance, has been named vice president (VP) of operations development; and Elaine Dymond​, who used to work at GlaxoSmithKline and Sanofi, is the new VP of quality.

Also, Ronald Overhiser​ joins as VP of innovation operations having previously worked at GE Healthcare Medical Diagnostics; and Evjatar Cohen, who has held a number of positions at Teva Pharmaceuticals, has been appointed VP of global portfolio management.

Quintiles ​has hired Vincent Aurentz​ as EVP, customer solutions business. Aurentz is heading a new unit of customer teams working across Quintiles’ clinical, commercial, capital and consulting divisions. Before joining Quintiles, Aurentz worked at Merck Serono.

Angela Panzarella​ has been named as president of ACM Global Central Lab​ as part of appointments at its US site. ACM has also hired Mary Williamson​ as director of laboratory operations and Andrew Bascom as director of data management and clinical systems.

Promotions have also been made from within ACM. Tracy Hendershot ​is now VP, clinical trials global operations and Brain Clark​ is the new senior business development director, North America.

Premier Research Group​ has named Christopher Codeanne​ as chief financial officer. Codeanne has worked for 20 years at companies including Oncology Development Partners, Averion International and Scirex.

Nathan Pienkowski​ has joined Pharmaceutical Institute​, a biopharm training provider, as institutional design director. Pienkowski has 15 years of course development and training experience. ​

Althea Technologies​ has appointed Catherine Mackey​ to its board of directors. Mackey has 28 years of biopharm experience working at Pfizer, Dekalb and Monsanto.

Kathleen Bloch​ has joined Laureate Pharma​ as chief financial officer. Bloch has worked at PC Group and Silver Line Building Products and will now be responsible for increasing capital at Laureate.